$CAPR So far the market is valuing the MESO partnership for late stage covid treatment at about 270 million. That would be a 3 bagger for our current market cap of 90 mil. Evox, codiak and now meso all recently getting lucrative deals who else is left in the exosome space beside CAPR? I have to think we are next..
  • 9
9 Likes